comparemela.com

Latest Breaking News On - Myelodysplastic syndromes recent updates - Page 1 : comparemela.com

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsData fromMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsData fromMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

Yazan madanatMyelodysplastic syndromesRecent updatesEvolving treatment paradigmsYear old man with lower riskMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

Treatment Approaches for Lower-Risk MDS With RAS Mutations

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Myelodysplastic syndromesRecent updatesEvolving treatment paradigmsMyelodysplastic syndromes recent updatesTreatment evolution myelodysplastic syndromesMds managementAsco 20232023 asco annual meetingAmerican society of clinical oncologyMds symptomsMds diagnosisMds presentationsHigh risk mdsLow risk mds

vimarsana © 2020. All Rights Reserved.